1. Smolej L. et al. Lowdose fludarabine and cyclophosphamide combined with rituximab is a safe and effective treatment option for elderly and comorbid patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: preliminary results of project Qlite, by the Czech CLL Study Group // Clin. Lymphoma Myeloma Leuk. 2011. Vol. 11. P. S261.
2. Mulligan S.P. et al. A randomised dose deescalation safety study of oral fludarabine, ±oral cyclophosphamide and intravenous rituximab (OFOCIR) as firstline therapy of fit patients with chronic lymphocytic leukaemia (CLL) aged ≥65 years: final analysis of response and toxicity // Blood. 2014. Vol. 124. P. 3325.
3. Nikitin E. et al. Randomised comparison of FCRLite And ClbR (chlorambucil plus rituximab) regimens in elderly patients with chronic lymphocytic leukemia // Hematologica. 2013. Vol. 98, suppl. 1. P. 473. Abstr. NS1147.
4. Foon K.A. et al. Longterm results of chemoimmunotherapy with lowdose fludarabine, cyclophosphamide and highdose rituximab as initial treatment for patients with chronic lymphocytic leukemia // Blood. 2012. Vol. 119, N 13. P. 3184–3185. DOI: https://doi.org/10.1182/blood201201408047
5. Shvidel L. et al. Conventional dose fludarabinebased regimens are effective but have excessive toxicity in elderly patients with refractory chronic lymphocytic leukemia // Leuk. Lymphoma. 2003. Vol. 44, N 11. P. 1947–1950. DOI: https://doi.org/10.1080/1042819031000110991
6. Marotta G. et al. Lowdose fludarabine and cyclophosphamide in elderly patients with Bcell chronic lymphocytic leukemia refractory to conventional therapy // Haematologica. 2000. Vol. 85, N 12. P. 1268–1270.
7. Abel G.A. The real world: CLL // Blood. 2011. Vol. 117, N 13. P. 3481–3482. DOI: https://doi.org/10.1182/blood201101328625 PMID: 21454464.
8. Swerdlow S.H. et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms // Blood. 2016. Vol. 127, N 20. P. 2375–2390. DOI: https://doi.org/10.1182/blood201601643569 Epub 2016 Mar 15. PMID: 26980727; PMCID: PMC4874220.
9. Sant M. et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project [published correction appears in Blood. 2011. Vol. 117, N 12. P. 3477] // Blood. 2010. Vol. 116, N 19. P. 3724–3734. DOI: https://doi.org/10.1182/blood201005282632
10. Dores G.M. et al. Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology // Br. J. Haematol. 2007. Vol. 139, N 5. P. 809–819. DOI: https://doi.org/10.1111/j.13652141.2007.06856.x
11. Злокачественные новообразования в России в 2018 году (заболеваемость и смертность) / под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. Москва : МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2019.
12. Kipps T.J. et al. Chronic lymphocytic leukaemia // Nat. Rev. Dis. Primers. 2017. Vol. 3. Article ID 16096. DOI: https://doi.org/10.1038/nrdp.2016.96 Epub 2017 Jan 19.
13. World Health Organization. World Health Statistics 2016: Monitoring Health for the SDGs Annex B: Tables of Health Statistics by Country. WHO Region and Globally, 2016.
14. National Cancer Institute Surveillance, Epidemiology, and End Results. Cancer Stat Facts: Leukemia – Chronic Lymphocytic Leukemia (CLL), 2020. URL: https://seer.cancer.gov/statfacts/html/clyl.html
15. Hallek M. et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL // Blood. 2018. Vol. 131, N 25. P. 2745–2760. DOI: https://doi.org/10.1182/blood201709806398
16. Weide R. et al. Survival improvement of patients with chronic lymphocytic leukemia (CLL) in routine care 1995–2017 // Leuk. Lymphoma. 2020. Vol. 61, N 3. P. 557–566. DOI: https://doi.org/10.1080/10428194.2019.1680840
17. Rai K.R. et al. Clinical staging of chronic lymphocytic leukemia // Blood. 1975. Vol. 46, N 2. P. 219–234. DOI: https://doi.org/10.1182/blood201608737650
18. Binet J.L. et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis // Cancer. 1981. Vol. 48, N 1. P. 198–206. DOI: https://doi.org/10.1002/10970142(19810701)48:1<198::aid cncr2820480131>3.0.co;2v
19. International CLLIPI Working Group. An international prognostic index for patients with chronic lymphocytic leukaemia (CLLIPI): a metaanalysis of individual patient data // Lancet Oncol. 2016. Vol. 17, N 6. P. 779–790. DOI: https://doi.org/10.1016/S14702045(16)300298
20. Rai K.R., Han T. Prognostic factors and clinical staging in chronic lymphocytic leukemia // Hematol. Oncol. Clin. North Am. 1990. Vol. 4, N 2. P. 447–456.
21. Mato A. et al. The Connect CLL Registry: final analysis of 1494 patients with chronic lymphocytic leukemia across 199 US sites // Blood Adv. 2020. Vol. 4, N 7. P. 1407–1418. DOI: https://doi.org/10.1182/bloodadvances.2019001145 PMID: 32271900; PMCID: PMC7160291.
22. Stilgenbauer S. et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial // Blood. 2014. Vol. 123, N 21. P. 3247–3254. DOI: https://doi.org/10.1182/blood201401546150
23. Ballman K.V. Biomarker: predictive or prognostic? // J. Clin. Oncol. 2015. Vol. 33, N 33. P. 3968–3971. DOI: https://doi.org/10.1200/ JCO.2015.63.3651
24. Gaidano G., Rossi D. The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment // Hematology Am. Soc. Hematol. Educ. Program. 2017. Vol. 2017, N 1. P. 329–337. DOI: https://doi.org/10.1182/ asheducation2017.1.329
25. Pal K. et al. GLASS: assisted and standardized assessment of gene variations from Sanger sequence trace data // Bioinformatics. 2017. Vol. 33, N 23. P. 3802–3804. DOI: https://doi.org/10.1093/bioinformatics/btx423